Medigene AG: Dr. Selwyn Ho appointed new CEO of Medigene

Experienced life sciences executive, physician and investor will lead Medigene starting 25 July 2022

Planegg/Martinsried (pta086/12.05.2022/18:40 UTC+2)

The Supervisory Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, today appointed Dr Selwyn Ho as a member of the Executive Management Board and as new Chief Executive Officer (CEO) of Medigene with effect of 25 July 2022. He accepted the appointments.

As a consequence, Prof. Dolores Schendel will step down as Chief Executive Officer at the end of 24 July 2022 and fully focus on her responsibilities as Chief Scientific Officer (CSO) and Head of Research and Development at Medigene.

Dr. Ho received his medical degree (MB BS) and Bachelor of Science (BSc) in Pharmacology from Imperial College, University of London, UK, and post-graduate qualifications (Dip Pharm Med) in Pharmaceutical Medicine from the Faculty of Pharmaceutical Physicians, Royal College of Physicians, UK. Adding to his medical and pharmaceutical background, he has over 20 years of international experience across Europe, US, and Asia in executive and senior management positions in both privately held and publicly traded biotech and pharma companies with a focus on inflammation and immunology, with various responsibilities in the areas of Product Development, Medical Affairs, Strategic Marketing and Market Access, Business Development and Licensing as well as Corporate Strategy and Financing.

Dr. Ho joins Medigene from Connect Biopharma (NASDAQ: CNTB), a global clinical-stage biopharmaceutical company developing therapies against chronic inflammatory diseases derived from T cell-driven research, where he held the position of Chief Business Officer and, amongst other responsibilities, jointly led the execution of the company IPO which closed in March 2021. Dr. Ho also serves as an Executive-In-Residence at New Rhein Healthcare Investors, a venture capital and growth stage fund focused on healthcare therapeutics and medical devices.

Dr. Selwyn Ho: "I am delighted to join Medigene as CEO at an important time for the company, with the recent partnering deal continuing to validate the strong scientific platform the company has developed in the field for T cell receptor-driven immunotherapies. I look forward to working with Dolores, the entire Medigene team and the Supervisory Board to build on the great work completed to date and to continue the journey to deliver innovative and differentiated immunotherapies that can transform the lives of patients with cancer."

Dr. Gerd Zettlmeissl, Chairman of Medigene's Supervisory Board: "It is a great pleasure for me to welcome Selwyn who has worked for many years for both large multinational biopharma companies as well as early stage, pre-commercialization biotech companies. With Selwyn, we have selected a leader who not only has in-depth knowledge of the life sciences sector, but also brings substantial experience in product development, product strategy and commercialization of numerous drugs as well as in corporate development and financing. We believe that Selwyn will optimally complement the current Medigene team and help maximize value creation for Medigene's shareholders."

Prof. Dolores Schendel, CEO and CSO at Medigene: "I am excited to welcome Selwyn to Medigene, and I very much look forward to working closely together to advance the vision for the company. For me, this is the optimal time to fully concentrate as CSO on advancing Medigene's research and development activities within our partnerships and for Medigene's own projects while transferring my other current responsibilities into the competent hands of Selwyn."

--- end of press release ---

About Medigene

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Planegg/Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to enhance T cell activity against solid cancers in fields of high unmet medical need.

Medigene's strategy is to develop its own therapies towards clinical proof-of-concept. In addition, the Company offers selected partners the opportunity to discover and develop therapies on the basis of its proprietary technology platforms. In return for such partnerships, Medigene expects to receive upfront and milestone payments as well as research and development funding and royalties on future product sales.

For more information, please visit https://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene

Dr. Anna Niedl
Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 3333 01
E-Mail:	investor@medigene.com
Website:	www.medigene.com
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate